226 related articles for article (PubMed ID: 24658317)
21. Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumors.
Furukori M; Imai K; Karasaki H; Watanabe K; Oikawa K; Miyokawa N; Taniguchi M; Furukawa H
World J Gastroenterol; 2014 Dec; 20(47):17949-54. PubMed ID: 25548493
[TBL] [Abstract][Full Text] [Related]
22. The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors.
Yang B; Chen HY; Zhang XY; Pan Y; Lu YF; Yu RS
Eur J Radiol; 2020 Mar; 124():108847. PubMed ID: 31991300
[TBL] [Abstract][Full Text] [Related]
23. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
24. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
25. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors.
Han X; Ji Y; Zhao J; Xu X; Lou W
Tumour Biol; 2013 Oct; 34(5):2871-9. PubMed ID: 23686804
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.
Lee L; Igarashi H; Fujimori N; Hijioka M; Kawabe K; Oda Y; Jensen RT; Ito T
Jpn J Clin Oncol; 2015 Dec; 45(12):1131-8. PubMed ID: 26378090
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.
Hill JS; McPhee JT; McDade TP; Zhou Z; Sullivan ME; Whalen GF; Tseng JF
Cancer; 2009 Feb; 115(4):741-51. PubMed ID: 19130464
[TBL] [Abstract][Full Text] [Related]
28. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Otani K; Asari S; Goto T; Terai S; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2016; 16(5):882-7. PubMed ID: 27350059
[TBL] [Abstract][Full Text] [Related]
29. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors.
Gao SW; Huang CS; Huang XT; Chen LH; Chen W; Cai JP; Yin XY
Pancreas; 2019 Jul; 48(6):795-798. PubMed ID: 31210659
[TBL] [Abstract][Full Text] [Related]
30. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
[TBL] [Abstract][Full Text] [Related]
31. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
[TBL] [Abstract][Full Text] [Related]
32. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria.
Ozkara S; Aker F; Yesil A; Senates E; Canbey C; Yitik A; Gonen C
Hepatogastroenterology; 2013 Oct; 60(127):1665-72. PubMed ID: 24627925
[TBL] [Abstract][Full Text] [Related]
33. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.
Cherenfant J; Stocker SJ; Gage MK; Du H; Thurow TA; Odeleye M; Schimpke SW; Kaul KL; Hall CR; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA; Talamonti MS
Surgery; 2013 Oct; 154(4):785-91; discussion 791-3. PubMed ID: 24074416
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
[TBL] [Abstract][Full Text] [Related]
36. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Validity of the American Joint Committee on Cancer Eighth Edition TNM Staging System for Surgically Treated and Well-Differentiated Pancreatic Neuroendocrine Tumors: A Comprehensive Analysis of 254 Consecutive Patients From a Large Chinese Institution.
Yang M; Zhang Y; Zeng L; Ke NW; Tan CL; Tian BL; Xiang B; Liu XB
Pancreas; 2019; 48(5):613-621. PubMed ID: 31091206
[TBL] [Abstract][Full Text] [Related]
38. Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region.
Wang SE; Su CH; Kuo YJ; Shyr YM; Li AF; Chen TH; Wu CW; Lee CH
Pancreas; 2011 Mar; 40(2):253-9. PubMed ID: 20966805
[TBL] [Abstract][Full Text] [Related]
39. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
